Importance of early immune recovery after autologous hematopoietic cell transplantation in lymphoma patients

References

• Jantunen E, Sureda A. The evolving role of stem cell transplants in lymphomas. Biol Blood Marrow Transplant. 2012;18:660–673.
   PubMed Web of Science ®Google Scholar
• Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant. 2015;50:1037–1056.
   PubMed Web of Science ®Google Scholar
• Passweg JR, Baldomero H, Bader P, et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2018;53:1139–1148.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Canals C, Rambaldi A, et al. Autologous stem cell transplantation in elderly patients (≥ or = 60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica. 2008;93:1837–1842.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Canals C, Attal M, et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2012;23:166–171.
   PubMed Web of Science ®Google Scholar
• d'Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–3099.
   PubMed Web of Science ®Google Scholar
• Kolstad A, Laurell A, Jerkeman M, et al. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood. 2014;123:2953–2959.
   PubMed Web of Science ®Google Scholar
• Allan DS, Keeney M, Howson-Jan K, et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:967–972.
   PubMed Web of Science ®Google Scholar
• Sauter C, Giralt S. The prognostic impact of peripheral blood progenitor cell dose following high-dose therapy and autologous stem cell transplant for hematologic malignancies. Leuk Lymphoma. 2015;56:1619–1625.
   PubMed Web of Science ®Google Scholar
• Zubair AC, Kao G, Daley H, et al. CD34(+)CD38(-) and CD34 (+) HLA-DR (-) cells in BM stem cell grafts correlate with short term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation. Cytotherapy. 2006;8:399–407.
   PubMed Web of Science ®Google Scholar
• Beksac M, Preffer F. Is it time to revisit our current hematopoietic progenitor cell quantification methods in the clinic. Bone Marrow Transplant. 2012;47:1391–1396.
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Mäntymaa P, Kuittinen T, et al. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor. Transfusion. 2012;52:1785–1791.
   PubMed Web of Science ®Google Scholar
• Valtola J, Varmavuo V, Ropponen A, et al. Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison. Transfusion. 2015;55:2358–2368.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Fruehauf S. Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens. Bone Marrow Transplant. 2011;46:627–635.
   PubMed Web of Science ®Google Scholar
• Saraceni F, Shem-Tov N, Olivieri A, et al. Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective. Bone Marrow Transplant. 2015;50:886–891.
   PubMed Web of Science ®Google Scholar
• Valtola J, Varmavuo V, Ropponen A, et al. Early immune recovery after autologous transplantation in non-Hodgkin lymphoma patients: predictive factors and clinical significance. Leuk Lymphoma. 2016;57:2025–2032.
   PubMed Web of Science ®Google Scholar
• Dean HF, Cazaly A, Hurlock C, et al. Defects in lymphocyte subsets and serological memory persist a median of 10 years after high-dose therapy and autologous progenitor cell rescue for malignant lymphoma. Bone Marrow Transplant. 2012;47:1545–1551.
   PubMed Web of Science ®Google Scholar
• Gaugler B, Arbez J, LeGouill S, et al. Characterization of peripheral blood stem cell grafts mobilized by granulocyte colony-stimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone. Cytotherapy. 2013;15:861–868.
   PubMed Web of Science ®Google Scholar
• Damiani D, Stocchi R, Masolini, et al. CD34+ -selected versus unmanipulated autologous stem cell transplantation in multiple myeloma: impact of dendritic and immune recovery and on complications due to infections. Ann Oncol. 2003;14:475–480.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood. 2001;98:579–585.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Inwards DJ, Micallef IN, et al. Early lymphocyte recovery post-autologous hematopoietic stem cell transplantation is associated with better survival in Hodgkin’s disease. Br J Haematol. 2002;117:629–633.
   PubMed Web of Science ®Google Scholar
• Gordan LN, Sugrue MW, Lynch JW, et al. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin’s and non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2003;31:1009–1013.
   PubMed Web of Science ®Google Scholar
• Kim H, Sohn HJ, Kim SE, et al. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant. 2004;34:43–49.
   PubMed Web of Science ®Google Scholar
• Yoong Y, Porrata LF, Inwards DJ, et al. The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin’s lymphoma. Leuk Lymphoma. 2005;46:1287–1294.
   PubMed Web of Science ®Google Scholar
• Boulassel MR, Herr AL, de Edwardes MD, et al. Early lymphocyte recovery following autologous peripheral stem cell transplantation is associated with better survival in younger patients with lymphoproliferative disorders. Hematology. 2006;11:165–170.
   PubMed Web of Science ®Google Scholar
• Joao C, Porrata LF, Inwards DJ, et al. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. Bone Marrow Transplant. 2006;37:865–871.
   PubMed Web of Science ®Google Scholar
• Tiwari D, Gao F, Hidalgo J, et al. Prognostic significance of early lymphocyte recovery after post-autografting administration of GM-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant. 2007;40:671–675.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Inwards DJ, Ansell SM, et al. Day 15 peripheral blood lymphocyte/monocyte ratio post-autologous peripheral hematopoietic stem cell transplantation and survival in diffuse large B-cell lymphoma. J Stem Cell Res Ther. 2011;1:1000103.
   Google Scholar
• Stover DG, Reddy VK, Shyr Y, et al. Long-term impact of prior rituximab therapy and early lymphocyte recovery on auto-SCT outcome for diffuse large B-cell lymphoma. Bone Marrow Transplant. 2012;47:82–87.
   PubMed Web of Science ®Google Scholar
• Romero Fernandez E, Montalban Bravo G, Arrieta Gallastegui R, et al. Lymphocyte recovery and infused CD34 cell dose: effect on the evolution after stem cell autotransplantation. Leuk Res Rep. 2013;2:54–57.
   PubMedGoogle Scholar
• Porrata LF, Inwards DJ, Ansell SM, et al. Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation. J Hematol Oncol. 2015;8:80.
   PubMed Web of Science ®Google Scholar
• Kim Y, Kim S-J, Cheong J-W, et al. Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma. Hematol Oncol. 2017;35:465–471.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Inwards DJ, Ansell SM, et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant. 2008;14:807–816.
   PubMed Web of Science ®Google Scholar
• Torka P, Wallace PK, Zhang Y, et al. Effect of immune reconstitution on survival after autologous hematopoietic cell transplant for B-cell non-Hodgkin lymphoma. Blood. 2015;126:3173.
   Google Scholar
• Holtan SG, Porrata LF, Inwards DH, et al. Timing of autologous transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma. Br J Haematol. 2006;133:628–633.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Burgstaler EA, Winters JL, et al. Immunologic autograft engineering and survival in non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2016;22:1017–1023.
   PubMed Web of Science ®Google Scholar
• Atta EH, Mello de Azevedo A, Maiolino A, et al. High CD8+ lymphocyte dose in the autograft predicts early lymphocyte count recovery after peripheral hematopoietic stem cell transplantation. Am J Hematol. 2009;84:21–28.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gastineau DA, Padley D, et al. Re-infused autologous graft natural killer cells correlate with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymphoma. 2003;44:116–124.
   Web of Science ®Google Scholar
• Yoon DH, Sohn BS, Jang G, et al. Higher infused CD34 + hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin’s lymphoma. Transfusion. 2009;49:1980–1990.
   Web of Science ®Google Scholar
• Porrata LF, Inwards DJ, Ansell SM, et al. Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma. J Blood Med. 2015;6:45–53.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Litzow MR, Inwards DJ, et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant. 2004;33:291–298.
   PubMed Web of Science ®Google Scholar
• Hiwase DK, Hiwase S, Bailey M, et al. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2008;14:116–124.
   PubMed Web of Science ®Google Scholar
• Valtola J, Silvennoinen R, Ropponen A, et al. Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison. Transfusion. 2016;56:1394–1401.
   PubMed Web of Science ®Google Scholar
• Bolwell B, Sobecks R, Pohlman B, et al. Etoposide (VP-16) plus G-CSF mobilizes different dendritic cell subsets than does G-CSF alone. Bone Marrow Transplant. 2003;31:95–98.
   PubMed Web of Science ®Google Scholar
• Holtan SG, Porrata LF, Micallef IN, et al. AMD3100 affects autograft lymphocyte collection and progression free survival in non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007;7:315–318.
   PubMedGoogle Scholar
• Gazzitt Y, Freytes CO, Akay C, et al. Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony stimulating factor in non-Hodgkin’s lymphoma patients. Stem Cells Dev. 2007;16:657–666.
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Mäntymaa P, Nousiainen T, et al. Blood graft composition after plerixafor injection in NHL patients. Eur J Haematol. 2012;89:128–135.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Markovic SN. Autograft mediated adoptive immunotherapy of cancer in the context of autologous stem cell transplantation. World J Clin Oncol. 2010;1:29–34.
   PubMedGoogle Scholar
• Jacobs B, Tognarelli S, Poller K, et al. NK cell subgroups, phenotype, and functions after autologous stem cell transplantation. Front Immunol. 2015;6:583.
   PubMed Web of Science ®Google Scholar
• Kansagra A, Inwards DJ, Ansell SM, et al. Infusion of autograft natural killer cell/CD14 + HLA-DRdim cell ratio predicts survival in lymphoma post autologous stem cell transplantation. Bone Marrow Transplant. 2018;53:146–154.
   PubMed Web of Science ®Google Scholar
• Campbell KS, Hasegawa J. Natural killer cell biology: an update and future directions. J Allergy Clin Immunol. 2013;132:536–544.
   PubMed Web of Science ®Google Scholar
• Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17:1025–1036.
   PubMed Web of Science ®Google Scholar
• Chiossone L, Dumas PY, Vienne M, et al. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18:671–688.
   PubMed Web of Science ®Google Scholar
• Murray S, Lundqvist A. Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: on being in the right place at the right time, with resilience. Hum Vaccin Immunother. 2016;12:607–611.
   PubMed Web of Science ®Google Scholar
• Daher M, Rezvani K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol. 2018;51:146–153.
   PubMed Web of Science ®Google Scholar
• Muraro PA, Robins H, Malhotra S, et al. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest. 2014;124:1168–1672.
   PubMed Web of Science ®Google Scholar